BMO reiterates Pfizer stock Outperform on pipeline strength By Investing.com

Pfizer’s Phase 3 sigvotatug vedotin trial in non-small cell lung cancer failed to show an overall survival benefit versus docetaxel, a mild negative for the oncology pipeline. BMO kept an Outperform rating with a $34 price target and said the miss is likely largely priced in, while Cantor Fitzgerald reiterated Neutral with a $27 target. Pfizer also reaffirmed 2026 guidance of $59.5B-$62.5B in revenue and $2.80-$3.00 adjusted EPS, despite the CFO transition.

Analysis

The market is treating this as a binary oncology miss, but the bigger issue is not the failed endpoint itself — it is the shrinking credibility of a late-stage asset that was supposed to help justify Pfizer’s post-COVID pipeline reset. In the near term, the stock’s high dividend yield creates a floor for income buyers, yet that same yield can become a trap if the market starts assigning more value to pipeline optionality than to cash return. The result is a classic “defensive multiple, offensive disappointment” setup: downside is limited by payout support, but upside likely stays capped until investors see a cleaner catalyst sequence.

Second-order, the read-through is more favorable for large-cap diversified pharma than for pure oncology-exposure names. When a company like PFE misses on a late-stage cancer program, capital typically rotates toward peers with broader earnings visibility and fewer single-asset binary risks; the real beneficiaries are other defensives that can absorb R&D volatility without pressuring guidance. That rotation can also spill into contract manufacturers and service providers only if Pfizer backfills spending with pipeline acceleration, which is not the base case over the next 1-2 quarters.

The contrarian angle is that the selloff may be overdone if investors are extrapolating one failed readout into a broader pipeline impairment. The key offset is that management reaffirmed the medium-term financial frame, which reduces the odds of near-term estimate cuts; that matters more than the headline trial miss for a stock trading on cash flow and payout durability. Over the next 3-6 months, the most important catalyst is whether the market believes the next credible pipeline updates can re-rate the name back toward yield-adjusted fair value.

Risk/reward improves only if the stock decouples from headline oncology noise and the next data points support pipeline breadth. Otherwise, this remains a low-beta hold rather than a momentum long, with the path higher likely driven by valuation support and income demand rather than fundamental acceleration.

Key Decisions for Investors

• Hold/underweight PFE into the next 2-4 weeks: downside from the trial miss is likely mostly absorbed, but upside should be capped until a new catalyst restores pipeline confidence; best entry for longs would be after post-event selling exhausts.
• Sell cash-secured puts on PFE with 1-3 month tenor at strikes 5-10% below spot: captures elevated implied uncertainty while expressing a view that dividend support limits further drawdown.
• Pair trade: long large-cap diversified pharma basket vs. short smaller oncology-heavy names for the next 1-2 quarters; the market is likely to reward earnings visibility over late-stage binary risk.
• If owning PFE for income, consider financing via covered calls 1-2 months out: modest upside participation remains, but the stock is more likely to mean-revert than trend immediately.
• Avoid chasing a rebound until the next pipeline readout: the best risk/reward is to wait for evidence that management can replace failed oncology optionality with another credible catalyst, likely over the next 3-6 months.